Webinar | March 27, 2024

MultiTAA-Specific T Cells: A Novel Treatment for Cancer

Source: bio-techne

T cell therapies are limited in their potential to treat cancer by their inability to target only a single antigen. While these therapies can initially provide a significant response, these treatments can eventually lead to tumor resistance through antigen escape mechanisms.

Explore a novel technique being introduced for targeting up to six antigens. The Multi-Antigen Targeted (MultiTAA) cell therapy approach is currently being utilized in clinical trials for treatment of hematological malignancies, displaying high safety and efficacy. Through this presentation you will gain insight into:

  • The enhanced patient outcomes achieved by targeting multiple antigens through MultiTAA T cell therapies
  • Notable process improvements carried out by Marker Therapeutics resulting in reduced manufacturing time, decreased contamination risks, and significant cost savings
  • Applications of MultiTAA in ongoing clinical trials to treat patients with acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL)
access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online